Lung transplantation offers an effective treatment modality for patients with end-stage chronic obstructive pulmonary disease (COPD). The exact determination of when to refer, list, and offer transplant as well as the preferred transplant procedure type remains unclear. Additionally, there are special considerations specific to patients with COPD being considered for lung transplantation, including the implications of single lung transplantation on lung cancer risk, native lung hyperinflation, and overall survival.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of the most important contributors to morbidity and mortality in the United States and remains the most common indication for lung transplantation worldwide [1 && ]. According to data from the International Society for Heart and Lung Transplantation (ISHLT) registry, there are more than one thousand lung transplants done every year for patients with severe COPD [2] . Despite the advancements in management, the threshold for considering lung transplantation in patients with severe COPD, the timing for listing, the surgical modality, and the use of single versus bilateral lung transplantation remains unclear. As the trajectory of illness in patients with COPD is highly variable and some patients have a longer protracted course of illness and longer transplant wait list times, consideration of lung transplantation could put these patients at a particular disadvantage [3] . Some practitioners also feel that utilization of the lung allocation scoring (LAS) in patient selection also puts these patients at a disadvantage compared with other chronic lung diseases [4] . In this review article, we aim to discuss indications, timing and, modality of lung transplant for COPD patients as well as discuss survival outcomes and some special considerations specific to the COPD population.
As mentioned in the previous section, the waiting time of patients with COPD are generally higher than other chronic lung diseases, including interstitial lung disease and cystic fibrosis [5 & ]. It remains unclear how to manage these patients and maintain their potential candidacy. Although lung volume reduction surgery (LVRS) has been associated with favorable outcomes in certain situations, given the more extreme fraction of expired volume in 1 s (FEV 1 ) cutoff recommendations for lung transplant compared with LVRS, only a small subset of potential LVRS candidates are also lung transplant candidates [6] . In carefully selected patients, LVRS can delay the need for lung transplantation [7] [8] [9] . Overall, though, the literature on the safety and impact of previous LVRS on future lung transplantation outcomes is underdeveloped. In 2014, Backhus et al. published their single-center experience of lung transplant following previous LVRS. Over a 15-year period, 36 patients receiving LVRS and transplant were compared with 138 patients receiving transplant alone. Operative and total hospital times were significantly longer in the combined group, and posttransplant survival was significantly decreased compared with the transplant-alone group. The total survival time, including time post-LVRS but prior to transplant, was similar in the combined (104 months) and transplant-alone group (96 months) [10] . Shigimura et al. in 2013 reported the outcomes of 25 LVRS and transplant patients compared with 25 matched transplant-alone patients from a single center. Although in-hospital mortality did not significantly differ between the two groups, previous LVRS patients had significantly higher rates of re-exploration for bleeding, renal injury requiring dialysis, and phrenic nerve injury as well as a diminished peak FEV 1 and 6-min walk distance posttransplant [11] .
Although previous surgical LVRS does not adversely affect perioperative transplant mortality, there is significantly added cost and patient morbidity as well as the need for two surgical procedures. The role of LVRS as a bridge to delayed lung transplantation deserves ongoing study.
There is even less published experience with endoscopic lung volume reduction prior to lung transplantation. Destors et al. published a case report of a patient with very severe emphysema receiving left-sided endoscopic placement of valves with resulting radiographic and spirometric improvements, but no symptomatic benefits. The patient subsequently underwent a contralateral lung transplant with no reported complications [12] . In a more recent matched case-control study, there were no differences in perioperative complications, length of stay, or 1-year mortality for COPD patients undergoing transplant after previous valve placement compared with those without valves. There were, though, higher rates of bacterial colonization, predominantly with stenotrophomonas [13] . Given concerns for infection in immunocompromised transplant recipients, further research is needed to assess the impact of increased bacterial colonization rates as well as the overall safety of endoscopic lung reduction in potential transplant candidates.
REFERRAL AND LISTING OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS FOR LUNG TRANSPLANTATION
In 2014, the ISHLT Pulmonary Council issued updated guidelines for referral and listing of patients with COPD [6] . These guidelines suggest that patients with a BODE Index (incorporating BMI, severity of airflow obstruction, level of dyspnea, and exercise capacity) of 5-6, progressive disease, significant hypercapnia and/or hypoxemia, and an FEV 1 less than 25% predicted should be referred for evaluation for potential lung transplantation. Earlier referral of patients with advanced COPD to a lung transplant center not only allows the transplant team to assess patients for transplant candidacy but also provides patients and their families the opportunity to make fully informed decisions.
There is no consensus amongst pulmonologist in determining the exact timing for listing patients with COPD for lung transplantation. The prebronchodilator or postbronchodilator FEV 1 , hypoxemia,
KEY POINTS
COPD remains the most common indication for lung transplantation worldwide and the second leading indication in the United States.
The association between improved survival with lung transplantation for COPD remains unclear and requires further study.
Single lung COPD lung transplant recipients are at an increased risk of acute native lung hyperinflation and native lung carcinoma.
Ongoing study is needed to determine the ideal timing and type of transplant for patients with COPD and likely varies based on individual patient characteristics as well as local demographics and organ allocation practices.
hypercapnia, low BMI, exercise capacity, low performance status on 6-min walk test and the subjective assessment of dyspnea have all been correlated to worsened outcomes in these patients but their utility in determining timing for referral is fairly limited [14] [15] [16] [17] . ISHLT consensus guidelines continue to use BODE index as a tool to guide timing of listing patients with COPD. Specifically, the Society recommended the cut-off of a BODE score of 7-10 for listing these patients [6] . This threshold is based on a study of 54 patients with COPD at two Swiss hospitals demonstrating improved median survival after transplant only in the subgroup with BODE greater than 7 [18] . Development of pulmonary hypertension heralds a poor prognosis and patients with moderate-to-severe pulmonary hypertension patients are similarly recommended for active listing. In a study utilizing the United Network for Organ Sharing (UNOS) database, conducted on 1243 patients with COPD listed for lung transplantation, severe pulmonary hypertension was associated with a hazard ratio for death of 7, highlighting the importance of monitoring pulmonary pressures in potential COPD transplant candidates [19 && ]. Patients with at least three severe COPD exacerbations in the previous year or an episode of acute hypercapnic respiratory failure are also at a significantly increased risk for death and are also recommended for active transplant listing [20, 21] .
SINGLE VERSUS BILATERAL LUNG TRANSPLANTATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
In the 1970s, early attempts at single lung transplant for COPD resulted in profound mismatches of ventilation and perfusion, leading to greater ventilation to the highly compliant emphysematous native lung with increased perfusion to the allograft [22] . Impaired allograft compliance secondary to ischemia reperfusion injury further worsened the ventilation-perfusion mismatch and was felt to make single lung transplant for COPD untenable. In the proceeding decades, as management of the allograft in the time after reperfusion improved, single lung transplantation was found to be safe, the impact of ventilation-perfusion mismatch was minimized, and single lung transplantation became the primary surgical technique for COPD patients [23] . Over the last several decades, though, bilateral lung transplantation has gradually become the predominant surgical technique in this patient population, constituting over 57% of all COPD lung transplant procedures reported to the ISHLT registry between January 1995 and June 2015 [24] . Potential survival differences between bilateral and single lung transplants are one rationale for the switch to bilateral procedures. Older retrospective studies indicated a survival benefit of bilateral over single lung transplantation for COPD [25] [26] [27] . These types of single-center retrospective studies have the potential for significant selection bias, as treatment decisions are difficult to control for in statistical models. Thabut et al. [28] demonstrated that while controlling for pretransplant baseline characteristics, bilateral lung transplant provided a mortality benefit over single lung transplant for patients that were less than 60 years old. [29] . Markov models simulating single versus bilateral allocation strategies for COPD demonstrate increased waitlist mortality utilizing bilateral allocation and similar total posttransplant survival time compared with prioritizing single lung allocation. Additionally, single lung prioritization maximized the total number of patients transplanted [30] . Given the societal impact of allocating limited resources, ongoing assessment of the risks and benefits of single versus bilateral lung transplant is needed. The optimal allocation strategy is likely dependent on age, patient level comorbidities (significant pulmonary hypertension, nodules, etc.), regional location and the prioritization of individual versus societal benefit.
ACUTE NATIVE LUNG HYPERINFLATION
In COPD recipients of single lung transplants, the compliance of the native lung is high compared with the allograft, and can be further magnified by edema in the transplanted lung resulting from primary graft dysfunction in the setting of ischemia reperfusion injury. The differences in lung compliance can lead to acute native lung hyperinflation, especially in the setting of positive pressure ventilation. Symptomatic acute native lung hyperinflation is characterized by hemodynamic instability and cardiac output as a result of decreased venous return and contralateral shift of the mediastinum towards the allograft resulting in extrinisic allograft compression, atelectasis, hypoxemia, and hypercapnia. Studies demonstrate an incidence of acute native lung hyperinflation of 15-30% [31, 32] . Techniques for minimizing the impact of acute native lung hyperinflation included independent lung ventilation with double-lumen endotracheal tubes, disconnecting the endotracheal tubes intermittently to allow native lung emptying and restore hemodynamic stability, early extubation, and ventilator manipulation, including reduced tidal volume and delivered breath frequency and increased inspiratory flow rates [31] . Risk factors for native lung hyperinflation include pulmonary hypertension, severe airways obstruction, and significant air trapping prior to transplantation. The potential deleterious impact of native lung hyperinflation, both acute and chronic, on transplant recipient posttransplant physiology provides rationale for bilateral lung transplant for selected COPD patients.
LUNG CANCER AFTER LUNG TRANSPLANTATION
Given the strong association of smoking with both COPD and lung cancer, COPD lung transplant recipients remain at high risk for bronchogenic carcinoma, predominantly after single lung transplantation. In a study of COPD recipients from seven United States transplant centers, 2% of patients developed subsequent lung cancer [33] . In a retrospective review of lung transplant recipients in Leuven, Belgium, 9.8% of single lung transplant recipients (including patients with COPD and fibrotic lung disease) developed subsequent bronchogenic carcinoma whereas only 1.8% of bilateral recipients developed lung cancer [34 && ]. Lung transplant physicians need to be vigilant for monitoring for native lung bronchogenic carcinoma, especially among single lung transplant recipients. The increased cancer risk identified in single lung recipients is often utilized as rationale for bilateral transplantation in this patient population.
SURVIVAL BENEFIT TO LUNG TRANSPLANTATION FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Patients undergoing transplant for COPD have good short-term survival, with an unadjusted 3-month mortality of 8-9% in the most recent ISHLT registry report [24] . Much of this low short-term mortality is because of the low risk of primary graft dysfunction resulting from ischemia reperfusion injury in the immediate posttransplant period [35, 36] . The more controversial question is whether transplant provides an overall mortality benefit to COPD patients. The literature on survival benefit is mixed, with the ability to make definitive conclusions on survival benefits hindered by changes and differences in organ allocation algorithms (time based, lung allocation score, urgency, etc.) as well as the potential for long-term survival with extremely impaired quality of life for advanced COPD patients in the absence of transplant. For example, Stavek et al. demonstrated no mortality benefit to transplant in a Norwegian cohort when comparing patients waiting for transplant to those receiving lung transplants [37] . Thabut et al. [38] identified patient level factors that predicted improved overall survival with transplantation compared with no transplant for COPD, including FEV 1 less than 16% predicted, lower BMI, younger age, and higher pulmonary arterial pressure.
The impact of risk factors leading to the development of COPD on overall transplant survival is also unclear. A recent single-center study demonstrates significantly higher 5 and 10 years survival for patients with COPD secondary to alpha-1-antitrypsin deficiency (AATD) compared with COPD patients without AATD (hazard ratio 1.7, 95% CI 1.02-2.82) [39] . A Swedish registry study similarly identified a survival benefit for lung transplant in patients with severe AATD (median survival 11 versus 5 years, P ¼ 0.006) [40] .
The literature on the impact of lung transplant on quality of life for patients with COPD is limited. A single-center study of 112 COPD patients demonstrates worsening quality of life with increasing BODE score. Importantly, patients with BODE 5-6 had similar improvements in quality of life to those with BODE 7-10, indicating that even patients not expected to have a mortality benefit with transplant should derive significant improvement in quality of life [41] . In the absence of definitive survival benefits, the discussion of transplant benefit for patients with COPD should focus on the potential quality of life benefits associated with the procedure. In our experience, the vast majority of COPD patients garner significant improvements in their quality of life after transplant. What remains unclear is the trajectory of the improvement in the posttransplant period, specifically the expected length of time the average patient should expect to have improved quality of life.
CONCLUSION
Despite significant advances in the treatment of COPD over the last several years, lung transplantation remains the only option available for many
